Halozyme Therapeutics
Price & Volume
Stats
See moreOpen | $48.03 |
Previous Close | $48.03 |
Day Range | $47.81-$48.03 |
52W Range | $33.15-$65.53 |
Market Cap | $6.1B |
Shares Short | 8M |
Financials
See moreRevenue (12 Mos) | $947.3M |
Revenue Growth (YoY) | 34.3% |
Gross Profit (12 Mos) | $454.2M |
Diluted EPS | $3.02 |
News
See moreYahoo Finance • 8 months ago
Halozyme to Report First Quarter 2024 Financial and Operating Results
Yahoo Finance • 11 months ago
Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis
Yahoo Finance • 11 months ago
Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Yahoo Finance • last year
Halozyme to Present at Upcoming Investor Conferences
About
CEO | Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. |
CFO | Ms. Nicole LaBrosse CPA |
Address | 12390 El Camino Real, San Diego, CA, United States, 92130 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 373 |
